Eli Lilly (LLY 0.40%) and Novo Nordisk (NVO 1.97%) are two phenomenal growth stocks that investors probably can't go wrong ...

Novo Nordisk is a global diabetes and weight loss leader with strong long-term growth prospects. Read why NVO stock is a ...

Novo Nordisk's pipeline, especially the oral GLP-1 and Alzheimer’s trial, offers significant long-term upside. Click here to ...

Novo Nordisk NVO shares have plunged 19.9% year to date, following a string of unfavorable outcomes, both pipeline and ...

SAP gains on cloud strength, NVO faces obesity setbacks, and TMO leans on AI and innovation amid macro headwinds.

Novo Nordisk A/S (NYSE:NVO) is one of the 10 Best Growth Stocks to Buy With Huge Upside Potential. On June 23, Novo Nordisk A ...

Novo Nordisk, a leading global healthcare company, is excited to announce a new Memorandum of Understanding with the Saudi ...

Novo Nordisk invests €2.34B to expand its Anagni facility near Rome, enhancing production of diabetes and obesity treatments ...

Wegovy® is indicated for chronic weight management in adults and adolescents (12+) with obesity or overweight and at least one related health condition. The once-weekly injectable supports weight loss ...

Cipla is preparing to enter the weight-loss drug making sector, heating the competition with US-based Eli Lilly & Co and Danish firm Novo Nordisk.

The Hims & Hers wellness platform announced Wednesday it will soon offer a generic version of the weight loss drug ...

For Immediate Release Chicago, IL – July 10, 2025 – Zacks.com announces the list of stocks featured in the Analyst Blog.